Английская Википедия:Agios Pharmaceuticals
Шаблон:Infobox company Agios Pharmaceuticals Inc. is a public American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias.[1] The company was founded in 2008 (or 2007)[2] by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts.[3][4] The company tendered an initial public offering in July 2013.[5]Шаблон:Rp
History
In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.[2]
In May 2016, the company announced it would launch partnership with Celgene,[6] developing metabolic immuno-oncology therapies and licensing AG-221 as well as AG-881 to Celgene, potentially garnering Agios $120 million in drug licensing payments.[7]
In April 2017, the company raised $250 million in a new stock offering in anticipation of FDA approval for its first cancer drug, Enasidenib[8]
In December 2017, the company filed a new drug application, or NDA, with the U.S. Food and Drug Administration, or FDA, for Ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia, or R/R AML with an IDH1 mutation.[9]
In November 2019, Agios announced an underwritten public offering of 8,250,000 shares of common stock at a price of $31.00 per share which would result in approximately $256 million aggregate gross proceeds.[10]
In April 2022, FDA approved PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for hemolytic anemia in adults with Pyruvate Kinase Deficiency.[11]
Corporate governance
Шаблон:As of, Agios' CEO is Brian Goff.[12]
Agios was established as a private company and converted to a public company with its initial public offering in July 2013 and subsequent listing on NASDAQ.[2][5]
References
- ↑ Шаблон:Cite web
- ↑ 2,0 2,1 2,2 Ошибка цитирования Неверный тег
<ref>; для сносокpollack2012не указан текст - ↑ Ошибка цитирования Неверный тег
<ref>; для сносокburns2012не указан текст - ↑ Ошибка цитирования Неверный тег
<ref>; для сносок10k2013не указан текст - ↑ 5,0 5,1 Ошибка цитирования Неверный тег
<ref>; для сносокhuggett2013не указан текст - ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite news
- ↑ Agios Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2017.
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- Английская Википедия
- Pharmaceutical companies of the United States
- Pharmaceutical companies established in 2008
- Companies based in Cambridge, Massachusetts
- Companies listed on the Nasdaq
- Health care companies based in Massachusetts
- 2013 initial public offerings
- 2008 establishments in Massachusetts
- American companies established in 2008
- Страницы, где используется шаблон "Навигационная таблица/Телепорт"
- Страницы с телепортом
- Википедия
- Статья из Википедии
- Статья из Английской Википедии
- Страницы с ошибками в примечаниях
